Indications
Inclisiran is a small interfering RNA (siRNA) that acts on the messenger RNA of proprotein convertase subtilisin kexin type 9 (PCSK9). It is used alongside diet and exercise to lower low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. It is also used in adults and in paediatric patients aged 12 years and older who have heterozygous familial hypercholesterolemia (HeFH), and in paediatric patients aged 12 years and older who have homozygous familial hypercholesterolemia (HoFH).
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA). Its sense strand is attached to triantennary N-Acetylgalactosamine (GalNAc), which helps liver cells (hepatocytes) take it up. Once inside the hepatocytes, inclisiran uses the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. That means more LDL-C receptors are recycled and more of them appear on the surface of the hepatocyte. The cell then takes up more LDL-C, and the level of LDL-C in the circulation falls.
Pregnancy & Breastfeeding
Women who are pregnant, or who could become pregnant, should be told that Inclisiran may carry a risk to the fetus. If a patient knows or suspects she is pregnant, she should tell her doctor so they can decide together whether Inclisiran should be stopped.
Nothing is known about whether inclisiran passes into human milk, what it might do to a breastfed baby, or whether it affects milk production. In animal studies, inclisiran was found in the milk of lactating rats at every dose given.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.